“Why didn’t anyone tell me about this virus?” is a frequent response I hear from parents upon learning their newborn is infected with cytomegalovirus or CMV. Although more than half of the U.S.

Please provide your email address to receive an email when new articles are posted on . Letermovir was first approved in 2017 for high-risk stem cell transplant recipients. CMV is relatively common in ...

− If Approved, Maribavir Would be the First and Only Inhibitor of CMV-specific UL97 Protein Kinase in the EU for Treatment of Adults with Post-transplant CMV Refractory (With or Without Resistance) to ...

Cytomegalovirus, or CMV, is a common infection in both adults and children. Clinical trials for several vaccines are currently underway to help prevent people from developing CMV. The Centers for ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that in the AURORA trial, a Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled ...

In a recent study posted to the medRxiv* preprint server, researchers evaluated the impact of cytomegalovirus (CMV) seropositivity on humoral and cellular immune responses generated after double ...

An experimental mRNA vaccine against human cytomegalovirus (CMV), a common virus that can infect babies during pregnancy, elicited some of the most promising immune responses to date of any CMV ...

- LIVTENCITY Is the First and Only Inhibitor of CMV-specific UL97 Protein Kinase Approved in China for the Treatment of Adults With Post-transplant CMV Infection/Disease Refractory* to Conventional ...